interested in understanding the following phenomenon in the chick embryo. If a chick limb bud is extirpated, the nerve cells that would have enervated the limb die. If an extra limb bud is transplanted to another embryo, new nerve fibers will enter the transplanted limb. Their research focused on how the periphery affected nerve fiber growth.
One of Dr. Hamburger's former students, Elmer Buecker, reported that if he grafted a fragment of a mouse tumor (Sarcoma 180) onto the body wall of a 3-day chick embryo, sensory nerve fibers entered the tumor. He concluded that the sarcoma was a favorable field for growth of sensory fibers. Dr. Levi-Montalcini, upon her arrival in St. Louis from her laboratory in Italy, decided to repeat this experiment. She found that both sympathetic and sensory fibers penetrated the tumor and also reached tissues they were not supposed to enter. Levi-Montalcini performed other experiments; instead of placing the tumor in the embryo, she put it where there were no nerve fibers (on the chorioallantoic membrane) and obtained the same results. She concluded that a soluble, diffusible agent was released from the tumor and stimulated the growth of the nerve cells. She then devised a hanging drop tissue culture system on glass slides in which a sensory ganglion from a chick embryo was placed in a plasma clot near a fragment of tumor. After 1 day of culture, she observed a cluster of nerve fibers emerging from the ganglion directed toward the tumor.
Neither Dr. Hamburger nor Dr. Levi-Montalcini were biochemists so they went to several of Washington University's departments looking for a biochemist "mad" enough to study this problem. I was interested in embryology and knew biochemistry so I thought, "I'll have a go at it."
It was a good combination; I knew very little about neuroembryology, and they knew very little about biochemistry so we interacted but never argued. As a biochemist, I ground up the tumor and made an extract. It worked! A crude extract prepared from the tumor made nerve fibers grow out from chick sensory ganglia when placed in culture (3). I thought the active agent was a protein because it was heat-labile, non-dialyzable, and inactivated by a protease but not by DNase or RNase.
During the 6-year period I labored on the problem, I continued my education in biochemistry by participating in the daily seminar and luncheon led by Arthur Kornberg in the Microbiology Department. Discussing papers in a group that included Paul Berg, Mel Cohen, Jerry Hurwitz, David Hogness, Dale Kaiser, Martin Kamen, and Bob Lehman was an education that could hardly have been improved. When I presented my results to this group, it was Kornberg who suggested I was dealing with a virus and that I should add some phosphodiesterase to destroy all known nucleic acids. I obtained some crude phosphodiesterase from one of his faculty members (Osamu Hayaishi) who was purifying it from snake venom. I incubated the enzyme preparation with my tumor extract and tested for nerve growth activity. The next day I saw the most incredible culture I had ever seen. The ganglion in culture had produced a massive number of nerve fibers in a single day. I first thought that the phosphodiesterase had removed an inhibitor that might have been present in the tumor extract. But no! In a control experiment it was the phosphodiesterase preparation itself that induced nerve fiber outgrowth. Further tests showed that it was not the diesterase but an impurity; a second protein was present in the preparation, which induced nerve growth. We purified this new biologically active protein from snake venom (4); it was thousands of times more potent than our best tumor-derived preparation. Its activity in cultures was inhibited by commercially available anti-snake venom serum, and amazingly, when Dr. Levi-Montalcini injected the purified venom protein into the yolk sac of chick embryos, it produced nerve fiber outgrowth identical to that produced by the transplanted tumor (5). I then pondered, "What could be the connection between nerve growth, tumors, and snake venom?" Nothing obviousbut I thought "where does snake venom come from, a modified salivary gland?" So, at random, I tested extracts of the salivary gland taken from a male mouse and found that it was just as potent as the snake venom protein in inducing nerve growth in cultures.
Crude extracts of the male mouse salivary gland were injected daily into newborn mice to test whether it affected nerve growth in the animal. Three effects were noted; not only did the sympathetic ganglia become greatly enlarged, but unexpectedly the mice opened their eyes earlier than normal (as early as 7 days after birth rather than the normal 12-14 days) and their teeth erupted earlier. Furthermore, a rabbit antiserum prepared against the purified salivary gland nerve growth factor, when injected into newborn mice, destroyed most of the sympathetic ganglion cells-a phenomenon subsequently called immunosympathectomy. These experiments indicated that the nerve growth factor indeed had a function in the developing animal (6 -8) .
Epidermal Growth Factor
At this point in my life I had started a family and decided it was time to get a more stable position rather than be supported on someone's research grant. As an assistant
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professor in the Biochemistry Department at Vanderbilt, I decided to leave the nerve growth area and study why crude extracts of the male mouse salivary gland induced early eyelid opening in the mouse. (The purified nerve growth factor did not affect eyelid opening.) My thought was that anything that enhanced a normal developmental process had to be of interest.
First, I examined histological sections of the eyelid area in control and treated animals. It became clear that precocious eyelid opening was because of an enhancement of epidermal growth and keratinization (9) . Based on the eyelid-opening assay, we were able to isolate the protein responsible for this effect and to determine the sequence and disulfide linkage of this 53-amino acid polypeptidenow known as epidermal growth factor (EGF) (8, 10 -12) . The question of whether EGF acted directly on the epidermis or via a secondary hormonal mechanism in the intact animal was answered by the observation that its direct addition to organ cultures of chick embryonic skin led to a marked increase in epidermal cell number and size (13)-hence the name.
Our laboratory then spent a number of years examining some of the metabolic effects of EGF on epidermal cultures (14 -17, 33) . I also distributed EGF to a number of other laboratories to test in their systems. Pedro Cuatrecasas discovered that, in culture, EGF stimulated the growth of human fibroblasts. I therefore thought there must be a receptor on human cells that could bind mouse EGF and also there must be an EGF-like molecule present in humans.
By this time we had another method for detecting and measuring EGF-a radio receptor assay using human fibroblasts and 125 I-labeled EGF in culture. By this method, we discovered that human urine contained an EGF-like molecule and we were able to purify it. This human protein, derived from urine, made human fibroblasts grow in culture; when we injected it into mice it made their eyelids open earlier. Therefore, we called it human EGF (hEGF). It was of similar size to murine EGF but slightly different in amino acid composition (18 -21) . At this same time in England, Dr. Gregory was investigating, as a possible ulcer treatment, a substance in urine (called urogastrone) that when injected into animals inhibited acid secretion in the stomach. From thousands of liters of urine they isolated urogastrone and found that it was a small protein that unexpectedly was identical to our human EGF, both in chemical composition and biological activity. Both urogastrone and hEGF inhibited acid secretion and stimulated cell growth.
In our laboratory we pursued the question: how does EGF make a cell grow and divide? In those days, it was thought that protein hormones did not enter cells but attached themselves to the receptors on the cell surface and then left after performing their task. We were able to label EGF and, thus, follow its fate after it bound to its receptor on the cell surface. (Three labeling methods were used: attaching radioactive iodine, a fluorescent molecule, or ferritin to the EGF molecule.) We finally concluded that EGF and its receptor were internalized into the cell in small membrane vesicles that eventually were degraded in lysosomes. However, we could not decide whether this internalization served merely to remove the receptor from the cell surface (desensitization) or was part of a signaling mechanism (22-24, 28, 41) .
As a biochemist I thought a hormone or growth factor should regulate some chemical reaction in a cell that might be demonstrable in a cell-free system. The only successful experiment in those days was Earl Sutherland's demonstration that adding glucagon to cell membranes stimulated the synthesis of cyclic AMP.
Fortunately, I had a friend at the National Institutes of Health (Dr. Joe DeLarco) who was surveying all of their stored cells for EGF receptors. He discovered and told me about a human squamous carcinoma cell (A431) that had millions of receptors per cell rather than the normal number of thousands per cell. I thought it should be easier to detect, in a cell-free system, a reaction that was regulated by EGF and its receptor. Membranes prepared from A431 cells were capable of binding massive amounts of EGF. The presence of EGF altered the morphology of these cells (25) and stimulated pinocytosis (26) . When we incubated these membranes with 32 P-labeled ATP, radioactivity was incorporated into the protein of the membrane. The addition of EGF to the incubation mixture greatly stimulated this reaction (27) .
As a biochemist, I was exhilarated! A cell-free system where EGF has an effect. When we examined what was phosphorylated in the membranes (by SDS-gel electrophoresis and autoradiography), we saw that in the presence of EGF, many proteins were phosphorylated, especially a protein of 170 kDa (29) . A protein of this size had been suggested by Das and Fox to be the molecular weight of the receptor for EGF. To isolate the receptor for EGF, I made an affinity column to which EGF was linked. Membranes from A-431 cells were solubilized in detergent and passed through the column. Only the solubilized receptor remained "stuck" on the column. It could be eluted by competition with soluble EGF and isolated. The isolated 170-kDa protein was able to bind EGF, had protein kinase activity dependent on ATP and EGF, and was itself phosphorylated. We concluded that the receptor was a transmembrane protein with at least three domains: an external EGF-binding domain, an internal kinase domain, and a domain that acted as a substrate which could be phosphorylated (30, (35) (36) (37) (38) 40) .
Originally we thought that threonine was the amino acid phosphorylated, because our analytical method did not distinguish it from tyrosine. When Tony Hunter reported a new method that could separate phosphothreonine from phosphotyrosine and that the transforming protein of the Rous sarcoma virus was a tyrosine kinase and not a threonine kinase, we reinvestigated the EGF receptor and determined that it, too, was a tyrosine kinase (31) . Originally it had been thought that the transforming protein was a foreign enzyme that interacted with the tyrosine residue and that was what caused cancer. However, the EGF receptor is a normal cellular protein with a normal cellular function. Nevertheless, the relationship was supported by the finding that antibodies to the Rous sarcoma transforming protein interacted with the EGF receptor (32) .
Our laboratory continued to explore the metabolic responses to EGF both in cell culture (33, (42) (43) (44) (45) (46) and in intact animals, aided by the discovery that phosphotyrosyl protein phosphatase activity was inhibited by vanadate (34, 52) . A number of EGF-dependent intracellular phosphorylated substrates were detected including the annexins (39, 53) , STAT proteins (48 -51) , and SHC (47, 48) . With regard to prepro-EGF, its presence in mouse kidney membranes and human urine as well as its biological activity were confirmed by isolation (54, 55) ; its cDNA was expressed as a glycosylated membrane protein in NIH 3T3 cells (56, 57) .
Epilogue
Since the initial discoveries of NGF and EGF, thousands of related papers and numerous reviews have been published revealing many new aspects of growth regulation. I can only mention a few. The receptors of many other growth factors and hormones have been found to be specific transmembrane, ligand-activated tyrosine kinases including the receptors for insulin and NGF; EGF-related loci are found in insects and round worms; the amino acid sequence of the transforming protein of the erythroblastosis virus is closely related to the amino acid sequence of the kinase domain of the EGF receptor; a family of EGFrelated molecules has been isolated; at least four EGF-related receptors, given various names, have been detected and one of them (Erb2) is overexpressed in some human breast tumors. This has led to more targeted clinical therapy.
None of the findings described in this brief personal history could have been possible without the efforts of many colleagues, students, and technicians, to all of whom I am most grateful. In the reference list of the publications from this laboratory, I have provided the titles of each paper to indicate the research area to which each investigator contributed. I also wish to acknowledge with gratitude the support of the National Institutes of Health and the American Cancer Society. Finally, on a personal note, I am both amazed and encouraged by the unpredictable scientific and clinical consequences of simply wondering what caused precocious eyelid openings in newborn mice.
Address correspondence to: stancohen@earthlink.net.
